Navigation Links
PharmAthene Reports First Quarter 2011 Financial and Operating Results
Date:5/11/2011

er the Company's SparVax™ program and the completion of patient dosing in the Phase I Valortim® dose escalation clinical trial, partially offset by the decrease in development expenses related to the Protexia® bioscavenger program, which was completed in 2010.

General and administrative expenses for the Company were $4.9 million and $5.3 million for the quarters ended March 31, 2011 and 2010, respectively.  The decrease in general and administrative expense during the most recent period resulted from cost reductions implemented during 2010 and a reduction in bad debt expense, partially offset by an increase in legal costs associated with the trial in the case against SIGA.

For the first quarter of 2011 PharmAthene's net loss attributable to common shareholders was $2.1 million, or $0.04 per share, compared to $7.9 million, or $0.28 per share, in the same period of 2010.  The year-over-year decrease in net loss includes the impact of the change in fair value of the Company's derivative instruments, which was $2.5 million for the three months ended March 31, 2011 compared to $0.3 million for the three months ended March 31, 2010. The decrease in fair value, which became a source of other income, was primarily associated with a decrease in PharmAthene's stock price from December 31, 2010 to March 31, 2011.

As of March 31, 2011, the Company had cash and cash equivalents, short-term investments, and net U.S. government accounts receivables and other receivables, including unbilled receivables, totaling approximately $18.7 million compared to $21.6 million at December 31, 2010.  The decrease at March 31, 2011 was primarily attributable to the net impact of cash used to fund operations.

"We continued to make steady progress in the first quarter of 2011 and achieved important program milestones," remarked Eric I. Richman, President and Chief Executive Officer. "We achieved several technical milestones with respect
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
2. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
3. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
4. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
5. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
6. PharmAthene Announces Pricing of $15 Million Public Offering
7. PharmAthene Announces Proposed Common Stock Offering
8. PharmAthene Announces $3.9 Million Registered Direct Offering
9. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
10. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
11. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain ... 100x better detail than the industry standard. But ... microscopy methods, it needed another medium to measure its ... of reference because it represents the highest standard of ... earliest discovery days of Ultralight Histology was to reverse ...
(Date:5/4/2015)... May 4, 2015   Tocagen Inc. , ... data from Tocagen,s ongoing investigational studies were presented ... the American Association of Neurological Surgeons (AANS)/Congress of ... 1-2, 2015, in Washington, D.C. ... a meeting with FDA and continues to advance ...
(Date:5/1/2015)... Md. , May 1, 2015  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... the $28.5 million second tranche of a $40 million ... Woodford first invested $25 million in NW ... Woodford entered into an agreement with the Company for ...
(Date:5/1/2015)... , May 1, 2015 /CNW/ - Softchoice, a leading North ... it is the proud recipient of two Cisco® Partner Summit ... Partner of the Year and Security Partner of the Year ... conference taking place this week in Montreal ... one, but two Cisco partner awards at this year,s conference," ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2
... Professor Harry Dorn has developed a new area of fullerene ... semiconductors and quantum computing applications. , Dorn plays with ... are tinker toys. First, in 1999, he figured out how ... do it reliably, how to change the number of atoms ...
... (Nasdaq: PRXL ), a leading global biopharmaceutical ... the,first quarter of Fiscal Year 2009 (ending September ... conjunction with the successful completion of the,acquisition of ... Josef von Rickenbach, Chairman and Chief Executive Officer ...
... Annual Meeting, FREMONT, Calif., Sept. 8 Vermillion, ... today that a,team of scientists at Stanford University and ... the Annual General Meeting of the,PAD Coalition. Led by ... T.,Fung, Chief Scientific Officer at Vermillion, Inc., the research ...
Cached Biology Technology:Carbon molecule with a charge could be tomorrow's semiconductor 2PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 4PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors 5Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 2Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 3
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... Nanoparticle films are no longer a delicate matter: Vanderbilt ... so they don,t disintegrate at the slightest touch. In ... to create nanoparticles ultrafine particles with diameters less than ... of different methods to mold them into thin films which ...
... that a new colon cancer screening technique created by ... it could potentially be as or more successful than ... technique uses optical technology, called low-coherence enhanced backscattering (LEBS) ... of the rectum. Light shines on the tissue, scatters, ...
... Sustainable Energy Technologies was chosen for multiple reasons: to ... change, to provide society with security of energy supply ... For this a European graduate school is thought to ... of thought, to foster the development of excellent young ...
Cached Biology News:Researchers create freestanding nanoparticle films without fillers 2Researchers create freestanding nanoparticle films without fillers 3Colon cancer screening technique shows continued promise in new study 2
... and finishing services are tailored to ... large-scale 5' screening or full length ... experience with large-scale genome projects and ... ideal cDNA outsourcing solution. In addition, ...
... Agencourt offers quick turnaround sequencing of individual ... and high copy plasmids. Agencourt's world-class, high ... Phred20 bases per day. The key ... service are 24 48 hour sample ...
Great for biotinylating DNA/RNA probes...
...
Biology Products: